Stay updated on Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The site revision tag was updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-20T01:32:00.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-12T21:34:16.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    Primary peritoneal carcinoma was added to the listed conditions and a new Resources entry for the Genetic and Rare Diseases Information Center was included; the revision notes indicate a version update from v3.4.1 to v3.4.2.
    Difference
    0.2%
    Check dated 2026-02-12T02:29:06.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1. This appears to be a minor backend/content management update with no changes to study content.
    Difference
    0.0%
    Check dated 2026-02-04T23:55:12.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    UI/text updates include adding a 'Show glossary' option, updating footer/version labels to 'No FEAR Act Data' and 'Revision: v3.4.0', and a capitalization change in 'Last Update Submitted that met QC Criteria'. The changes are minor and do not affect core study information or functionality (To avoid being alerted by small changes, set an alert condition by clicking below.)
    Difference
    0.2%
    Check dated 2026-01-28T21:25:23.000Z thumbnail image
  8. Check
    82 days ago
    Change Detected
    Summary
    Updated page revision label to v3.3.4 and removed the previous v3.3.3 label. This metadata update does not alter study details, eligibility criteria, or results.
    Difference
    0.0%
    Check dated 2026-01-14T03:13:04.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page.